Hasserjian R - Search Results

1

Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.

Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Patnaik MM, et al. Among authors: hasserjian r. Leukemia. 2022 Dec;36(12):2934-2938. doi: 10.1038/s41375-022-01754-3. Epub 2022 Nov 5. Leukemia. 2022. PMID: 36335264 No abstract available.

2

Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.

Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN. Wang SA, et al. Leuk Res. 2011 Mar;35(3):351-7. doi: 10.1016/j.leukres.2010.07.018. Epub 2010 Aug 5. Leuk Res. 2011. PMID: 20691474

3

Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.

Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SA. Ok CY, et al. Among authors: hasserjian rp. Leukemia. 2014 Jan;28(1):185-9. doi: 10.1038/leu.2013.191. Epub 2013 Jun 21. Leukemia. 2014. PMID: 23787392 No abstract available.

4

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A. Wang SA, et al. Among authors: hasserjian rp. Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13. Blood. 2014. PMID: 24627528 Free PMC article.

5

Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.

Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Pozdnyakova O, et al. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):253-61. doi: 10.1016/j.clml.2014.11.002. Epub 2014 Nov 18. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25515354 Review.

6

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Steensma DP, et al. Among authors: hasserjian rp. Blood. 2015 Jul 2;126(1):9-16. doi: 10.1182/blood-2015-03-631747. Epub 2015 Apr 30. Blood. 2015. PMID: 25931582 Free PMC article.

7

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.

Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA. Peng J, et al. Leuk Lymphoma. 2016;57(4):812-9. doi: 10.3109/10428194.2015.1079318. Epub 2016 Mar 4. Leuk Lymphoma. 2016. PMID: 26293512

8

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. Arber DA, et al. Among authors: hasserjian r. Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Blood. 2016. PMID: 27069254 Free article. Review.

9

Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.

Petrova-Drus K, Hasserjian R, Pozdnyakova O, Dal Cin P, Mathew S, Margolskee E, Orazi A, Geyer JT. Petrova-Drus K, et al. Among authors: hasserjian r. Leuk Lymphoma. 2017 Mar;58(3):569-577. doi: 10.1080/10428194.2016.1203432. Epub 2016 Jul 7. Leuk Lymphoma. 2017. PMID: 27389864

10

Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP. Wang SA, et al. Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15. Mod Pathol. 2016. PMID: 27443511 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

300 results

Search Page